XFOR X4 Pharmaceuticals, Inc.

NASDAQ
$3.18

X4 Pharmaceuticals, Inc. (XFOR) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.6% since its last earnings release on November 4, 2026.

X4 Pharmaceuticals Beat Consensus Estimates
Wednesday, November 4, 2026 · 4:15 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:15 PM ET
Earnings Whisper
-
vs ($0.22)
Rev est $2.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.12

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.